secwatch.observer — SEC 8-K summary
======================================

Issuer:     Peak Bio, Inc. (—)
CIK:        0001834645
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-097086
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Peak Bio appoints Sandip Patel as director and Audit Committee chair
--------------------------------------------------------------------

- Sandip Patel appointed as Class III director and Audit Committee chair effective August 8, 2024.
- Patel participated in May and July 2024 financings totaling $275,500.
- He brings experience in biotech M&A and finance; previously served as General Counsel at WellCare.
- No family relationships or arrangements with other directors or officers.
- Board cites his advisory background in biopharma for appointment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024097086/0000950170-24-097086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834645/000095017024097086/pkbo-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-097086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer